Correction to: Efficacy and safety of an adsorbent and anti-oxidative vaginal gel on CIN1 and 2, on high-risk HPV, and on p16/Ki-67: a randomized controlled trial

Attila Louis Major^{1,2} · Vladimír Dvořák³ · Jana Schwarzová⁴ · Aleš Skřivánek⁵ · Tomáš Malík⁶ · Marek Pluta⁷ · Ivanna Mayboroda⁸ · Etienne Marc Grandjean^{9,10}

Published online: 7 January 2021

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: Archives of Gynecology and Obstetrics
<https://doi.org/10.1007/s00404-020-05816-8>

In the original article published, there was an error in figure 2. “Fehlt Rahmen links” was a comment in German as an information that the frame was missing in figure 2. The

typesetter misunderstood this correction. The correct word is “**Cytology at Baseline**” and this 2 times (for the active as well as for the control group) in Fig. 2.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s00404-020-05816-8>.

✉ Attila Louis Major
majorattila@outlook.fr

¹ Femina Gynecology Center, Rue Emile-Yung 1, 1205 Geneva, Switzerland

² Department of Obstetrics and Gynecology, Cantonal Hospital, University of Fribourg, Fribourg, Switzerland

³ Centrum ambulantní Gynekologie a primární péče, s.r.o., Brno, Czech Republic

⁴ Smetanova 388, 252 64 Velké Prilepy, Prague-West, Czech Republic

⁵ G-CENTRUM Olomouc, s.r.o., Olomouc, Czech Republic

⁶ Gyneko spol. s.r.o., Vsetín, Czech Republic

⁷ Fakultní Nemocnice v Motole (University Hospital Motol), Onkogynekologická a kolposkopická Ambulance, Praha, Czech Republic

⁸ Department of Obstetrics and Gynecology, University Hospital of Geneva, Geneva, Switzerland

⁹ Phidalsa Pharma-Consultants, Petit-Lancy/Geneva, Switzerland

¹⁰ Camara-Partners, Consultant, Nyon, Switzerland

ACTIVE ARM										
Cytology at Baseline		Cytological Findings at visit 4 (6 months)							Remission + Regression	Progression
		NILM	ASC-US	AGC	LSIL	ASC-H	HSIL	Drop-out		
NILM	6	6								
ASC-US	21	16	4		1			1	16 (76.2%)	1 (4.8%)
AGC	1	1							1 (100.0%)	
LSIL	59	36	10	1	9	2	1		47 (79.7%)	3 (5.1%)
ASC-H	6	4	2					3	6 (100.0%)	
HSIL	9	2	2		1	3	1	2	8 (88.9%)	
Total	102	65	18	1	11	5	2	6	*78 (76.5%)	4 (3.9%)

CONTROL ARM										
Cytology at Baseline		Cytological Findings at visit 4 (6 months)							Remission + Regression	Progression
		NILM	ASC-US	AGC	LSIL	ASC-H	HSIL	Drop-out		
NILM	1				1					1 (100.0%)
ASC-US	24	6	7		7	4		1	6 (25.0%)	11 (45.8%)
AGC	1				1					1 (100.0%)
LSIL	59	6	8		40	4	1		14 (23.7%)	5 (8.5%)
ASC-H	17	4	4		6	2	1		14 (82.4%)	1 (5.9%)
HSIL	5	1	1		2	1			5 (100.0%)	
Total	107	17	20		57	11	2	1	*39 (36.4%)	19 (17.8%)

Shadings illustrate different cytological changes. Dark grey: remission to non-conspicuous finding or regression to a lower grade. Grey: persistence. Light grey: progression to a higher grade.

NILM: Negative for Intraepithelial Lesion or Malignancy; ASC-US: Atypical Squamous Cells of Undetermined Significance; AGC: Atypical Glandular Cells ; ASC-H: Atypical Squamous Cells cannot exclude HSIL; LSIL: Low grade Squamous Intraepithelial Lesion; HSIL: High grade Squamous Intraepithelial Lesion

* Fisher's two tailed exact test and Pearson's chi-squared test; $p < 0.001$

Fig. 2 Difference in cytological findings after 6 months in the active and control arm. Shadings illustrate different cytological changes. Dark grey, remission to non-conspicuous finding or regression to a lower grade. Grey, persistence. Light grey, progression to a higher grade. NILM, negative for intraepithelial lesion or malignancy;

ASC-US, atypical squamous cells of undetermined significance; AGC, atypical glandular cells; ASC-H, atypical squamous cells cannot exclude HSIL; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion. *Fisher's two-tailed exact test and Pearson's chi-squared test; $p < 0.001$

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.